NasdaqGS:DFTXPharmaceuticals
What Do Definium Therapeutics (DFTX) Phase 3 GAD Results Mean For DT120?
Definium Therapeutics (NasdaqGS: DFTX) reported positive topline Phase 3 Voyage study results for DT120 ODT in adults with generalized anxiety disorder.
The trial met its primary and secondary efficacy endpoints versus placebo, with a statistically significant and clinically meaningful benefit.
The data may support upcoming regulatory filings for DT120 ODT in generalized anxiety disorder, addressing a large unmet treatment need.
This kind of progress in generalized anxiety disorder...